March 5, 2021

Pharmaceutical Merck earns 5,585 million until June, 128% more



The chemical and pharmaceutical group Merck announced on Tuesday that it has earned 5,585 million dollars until June of this year, more than double at the interannual level, driven by a sharp increase in sales of its cancer products and vaccines for humans.

The turnover of the company, which is based in Kenilworth (New Jersey), reached 22,575 million in the first half, 10% more compared to the same tranche of 2018.

As for the second quarter, to which most analysts paid attention on Wall Street, the company increased its attributed profit by 56%, to 2,670 million dollars.

Revenues between April and June amounted to 11,760 million, an increase of 12% compared to that period of the previous year, which is explained by a higher turnover in the pharmaceutical business.

Of particular note were the sales of its immune drug Keytruda, which shot up 58% between April and June, to $ 2,634 million.

Sales of the Varivax chickenpox vaccine also rose by a remarkable 58%, reaching 675 million, while those of the Gardasil human papillomavirus increased 46%, to 886 million.

In contrast, sales of its star drug for Zetia cholesterol fell 39%, reaching 232 million, and those of the drug Isentress for the treatment of HIV infection fell 19%, to 247 million.

The president and CEO of Merck, Kenneth Frazier, stressed that the firm follows a strategy based on the advancement of science, which has contributed to the growth of turnover during the quarter and the strengthening of its product offering.

For the year 2019 as a whole, the company decided to increase its billing forecasts to a range between 45,200 and 46,200 million dollars.

Likewise, the firm reported acquisitions such as that of the Peloton firm, which will involve a charge of 1,100 million dollars in the next results, so its annual profit estimates are reduced to a fork between 3.78 and 3.88 dollars per share

The results exceeded analyst expectations and an hour and a half after the opening of the session at the New York Stock Exchange, Merck's titles advanced 1.32% in the Dow Jones group of Industrialists.

. (tagsToTranslate) pharmaceutical (t) Merck (t) earns (t) millions (t) June



Source link